Tongxinluo Capsule
Cross-source consensus on Tongxinluo Capsule from 1 sources and 5 claims.
1 sources · 5 claims
Uses
Dosage & preparation
Comparisons
Background
Evidence quality
Highlighted claims
- Tongxinluo capsule is a Chinese patent medicine based on traditional herbal theory, approved by China's State Food and Drug Administration in 1996 for angina pectoris and ischaemic stroke. — Adjunctive Tongxinluo capsule for patients with acute coronary syndromes undergoing percutaneous coronary intervention: a GRADE-assessed systematic review and meta-analysis of randomised controlled trials
- Tongxinluo capsule is included in China's National List of Essential Medicines and is widely used for ACS patients undergoing PCI. — Adjunctive Tongxinluo capsule for patients with acute coronary syndromes undergoing percutaneous coronary intervention: a GRADE-assessed systematic review and meta-analysis of randomised controlled trials
- Each Tongxinluo capsule contains 0.26 g of formulation, with dosing in trials ranging from 2 to 4 capsules three times daily. — Adjunctive Tongxinluo capsule for patients with acute coronary syndromes undergoing percutaneous coronary intervention: a GRADE-assessed systematic review and meta-analysis of randomised controlled trials
- No prior systematic review had specifically evaluated Tongxinluo in the ACS-PCI population before this study. — Adjunctive Tongxinluo capsule for patients with acute coronary syndromes undergoing percutaneous coronary intervention: a GRADE-assessed systematic review and meta-analysis of randomised controlled trials
- Prior individual studies and a Cochrane systematic review had suggested TXL may reduce restenosis and recurrent cardiovascular events in patients with coronary heart disease after PCI. — Adjunctive Tongxinluo capsule for patients with acute coronary syndromes undergoing percutaneous coronary intervention: a GRADE-assessed systematic review and meta-analysis of randomised controlled trials